UA100372C2 - Выделенный пептид, способный индуцировать цитотоксические т-клетки, и его применение в качестве вакцины - Google Patents

Выделенный пептид, способный индуцировать цитотоксические т-клетки, и его применение в качестве вакцины

Info

Publication number
UA100372C2
UA100372C2 UAA200909469A UAA200909469A UA100372C2 UA 100372 C2 UA100372 C2 UA 100372C2 UA A200909469 A UAA200909469 A UA A200909469A UA A200909469 A UAA200909469 A UA A200909469A UA 100372 C2 UA100372 C2 UA 100372C2
Authority
UA
Ukraine
Prior art keywords
cells
vaccine
isolated
peptid
application
Prior art date
Application number
UAA200909469A
Other languages
English (en)
Ukrainian (uk)
Inventor
Такуя Цунода
Рюдзі Охсава
Original Assignee
Онкотерапі Саєнс, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Онкотерапі Саєнс, Інк. filed Critical Онкотерапі Саєнс, Інк.
Publication of UA100372C2 publication Critical patent/UA100372C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001122—Ephrin Receptors [Eph]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/422—Ephrin Receptors [Eph]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4225—Growth factors
    • A61K40/4229—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4251—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)

Abstract

Изобретение относится к выделенному пептиду, способному индуцировать цитотоксические Т-клетки, фармацевтической композиции, которая его содержит, эксзосоме, которая экспрессирует на своей поверхности комплекс, включающий данный пептид, способу индуцирования антигенпрезентирующей клетки. Изобретение также относится к способу индуцирования цитотоксичных Т-клеток, вакцине для ингибирования пролиферации клеток, способу скрининга пептида и т.п.
UAA200909469A 2007-02-21 2008-02-21 Выделенный пептид, способный индуцировать цитотоксические т-клетки, и его применение в качестве вакцины UA100372C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90294907P 2007-02-21 2007-02-21

Publications (1)

Publication Number Publication Date
UA100372C2 true UA100372C2 (ru) 2012-12-25

Family

ID=39709837

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200909469A UA100372C2 (ru) 2007-02-21 2008-02-21 Выделенный пептид, способный индуцировать цитотоксические т-клетки, и его применение в качестве вакцины

Country Status (27)

Country Link
EP (20) EP2476694B1 (ru)
JP (6) JP5239103B2 (ru)
KR (8) KR101511140B1 (ru)
CN (4) CN104292299B (ru)
AR (1) AR068302A1 (ru)
AU (1) AU2008218463B2 (ru)
BR (1) BRPI0808421B1 (ru)
CA (3) CA2678755C (ru)
CO (1) CO6190536A2 (ru)
CY (2) CY1114590T1 (ru)
DK (3) DK2465864T3 (ru)
ES (6) ES2435194T3 (ru)
HR (3) HRP20131044T1 (ru)
IL (10) IL200478A (ru)
MX (4) MX2009009022A (ru)
MY (2) MY173379A (ru)
NZ (4) NZ579768A (ru)
PH (1) PH12014501642B1 (ru)
PL (3) PL2121731T3 (ru)
PT (2) PT2121731E (ru)
RU (1) RU2464275C2 (ru)
SG (3) SG10201506589WA (ru)
SI (3) SI2465864T1 (ru)
TW (5) TWI596109B (ru)
UA (1) UA100372C2 (ru)
WO (1) WO2008102557A1 (ru)
ZA (1) ZA200905881B (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1660677A2 (en) 2003-08-20 2006-05-31 Oncotherapy Science, Inc. Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)
ES2632123T3 (es) 2007-08-20 2017-09-11 Oncotherapy Science, Inc. Péptido CDH3 y agente medicinal que comprende el mismo
ES2534437T3 (es) 2008-06-30 2015-04-22 Oncotherapy Science, Inc. Anticuerpos anti-CDH3 marcados con etiqueta de radioisótopo y usos de los mismos
TW201008574A (en) * 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
TWI580431B (zh) 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
SG195571A1 (en) * 2008-10-22 2013-12-30 Oncotherapy Science Inc Rab6kifl/kif20a epitope peptide and vaccines containing the same
TWI539160B (zh) 2008-12-05 2016-06-21 腫瘤療法 科學股份有限公司 Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
WO2010073551A1 (en) 2008-12-24 2010-07-01 Oncotherapy Science, Inc. C1orf59 peptides and vaccines including the same
TW201102081A (en) * 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
US8703808B2 (en) 2009-06-23 2014-04-22 Centre National De La Recherche Scientifique Use of derivatives of indoles for the treatment of cancer
WO2011080796A1 (en) 2009-12-28 2011-07-07 Oncotherapy Science, Inc. Anti-cdh3 antibodies and uses thereof
ES2575160T3 (es) 2010-03-15 2016-06-24 The Board Of Trustees Of The University Of Illinois Inhibidores de las interacciones que unen la subunidad alfa de la beta integrina-proteína G
TWI538685B (zh) * 2010-04-02 2016-06-21 腫瘤療法 科學股份有限公司 Ｅｃｔ２胜肽及含此胜肽之疫苗
SG190407A1 (en) * 2010-12-02 2013-06-28 Oncotherapy Science Inc Tomm34 peptides and vaccines including the same
KR102355121B1 (ko) * 2011-12-14 2022-02-09 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 암 요법을 위한 병립 유전자 비활성화 생물표식과 표적들
SG11201405578TA (en) 2012-03-09 2014-11-27 Oncotherapy Science Inc Pharmaceutical composition containing peptide
WO2014010232A1 (en) * 2012-07-10 2014-01-16 Oncotherapy Science, Inc. Ly6k epitope peptides for th1 cells and vaccines containing the same
JP6259983B2 (ja) * 2012-07-10 2018-01-17 オンコセラピー・サイエンス株式会社 Ｔｈ１細胞のＫＩＦ２０Ａエピトープペプチドおよびこれを含有するワクチン
WO2014034754A1 (ja) * 2012-08-31 2014-03-06 塩野義製薬株式会社 Psf1由来ペプチド
DK2895600T3 (da) 2012-09-11 2020-04-27 Onco Therapy Science Inc Ube2t-peptider og vacciner, der indeholder disse
WO2014141652A1 (en) * 2013-03-11 2014-09-18 Oncotherapy Science, Inc. Smyd3 peptides and vaccines containing the same
TWI658049B (zh) * 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
US20160166666A1 (en) * 2013-07-12 2016-06-16 Sumitomo Dainippon Pharma Co., Ltd. Tumor antigen peptide
JP2015227292A (ja) * 2014-05-30 2015-12-17 国立大学法人高知大学 膵がん細胞浸潤転移抑制ワクチン
BR112016030740A2 (pt) 2014-07-01 2018-02-20 Pfizer Inc. diacorpos heterodiméricos biespecíficos e seus usos
ES2856834T3 (es) * 2014-08-04 2021-09-28 Oncotherapy Science Inc Péptido derivado de URLC10 y vacuna que contiene el mismo
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
CN104975082B (zh) * 2015-06-05 2018-11-02 复旦大学附属肿瘤医院 一组用于评估肺癌预后的基因及其应用
FI3436048T3 (fi) * 2016-03-31 2025-09-15 Biontech Us Inc Neoantigeeneja ja niiden käyttömenetelmiä
CN110214144B (zh) * 2016-11-16 2023-05-02 深圳华大生命科学研究院 多肽及其应用
EP4649954A3 (en) 2017-01-25 2025-12-17 Ose Immunotherapeutics Method for manufacturing a stable emulsion for peptide delivery
WO2018183447A1 (en) * 2017-03-28 2018-10-04 Zhenglun Zhu Methods of treating neoplastic diseases
CN110997903B (zh) * 2017-08-10 2024-03-29 古德T细胞有限公司 用于癌症治疗的t细胞的活化方法
EP4036235A1 (en) * 2018-02-15 2022-08-03 National University Corporation Asahikawa Medical University Cancer antigen peptide
KR102335916B1 (ko) * 2019-04-22 2021-12-08 한국과학기술연구원 인간 백혈구 항원 a02:01 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
KR102322832B1 (ko) * 2019-04-22 2021-11-12 한국과학기술연구원 인간 백혈구 항원 a24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
CN113117055A (zh) * 2019-12-31 2021-07-16 上海细胞治疗集团有限公司 一种特异性结合hla-a24分型的多肽组合物及应用
CN117143206B (zh) * 2023-08-03 2024-09-03 华南农业大学 Alv-j mhc-b21限制性表位肽及其筛选方法和应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
NZ217727A (en) * 1985-10-03 1990-05-28 Genentech Inc Nucleic acid encoding alpha or b chain of inhibin, its production and compositions containing it
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2084180A1 (en) * 1991-12-11 1993-06-12 Paul P. Hung Expression of specific immunogens using viral antigens
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
EP0756627A1 (en) * 1994-04-15 1997-02-05 Amgen Inc. Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US20030198642A1 (en) 1995-08-03 2003-10-23 Johannes J. Geuze Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
EP0960204A4 (en) 1996-07-26 2002-01-23 Sloan Kettering Inst Cancer METHODS AND REAGENTS FOR GENETIC IMMUNIZATION
WO1998045433A1 (en) * 1997-04-04 1998-10-15 Board Of Regents, The University Of Texas System Proteins and compositions for modulating mitosis
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US20020102542A1 (en) * 1997-10-07 2002-08-01 Daikichi Fukushima Polypeptide, cdna encoding the polypeptide, and use of the both
US20070014787A1 (en) * 1998-07-15 2007-01-18 Human Genome Sciences, Inc. 71 human secreted proteins
WO2001029221A2 (en) * 1999-10-20 2001-04-26 Zymogenetics, Inc. Proteins and polynucleotides encoding them
US6682902B2 (en) * 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
US20030013649A1 (en) * 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
CN1469926A (zh) * 2000-03-29 2004-01-21 科里克萨有限公司 治疗和诊断肺癌的组合物和方法
AU2001277172A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-trans protein and related reagents and methods of use thereof
US6830885B1 (en) * 2000-08-18 2004-12-14 Phenogene Therapeutiques Inc. Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature
US20090062512A1 (en) * 2000-10-10 2009-03-05 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
CN100400099C (zh) * 2001-01-04 2008-07-09 北京迪威华宇生物技术有限公司 预防和治疗人前列腺癌的重组蛋白疫苗
US20040236091A1 (en) * 2001-03-28 2004-11-25 Chicz Roman M. Translational profiling
CA2444691A1 (en) * 2001-04-18 2002-10-31 Protein Design Labs, Inc. Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
EP1517998A2 (en) * 2001-06-18 2005-03-30 EOS Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20030124579A1 (en) * 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
AU2003217966A1 (en) * 2002-03-07 2003-10-08 Licentia, Ltd. Lymphatic and blood endothelial cell genes
US20030194704A1 (en) * 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
US20070015271A1 (en) * 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
US20070224201A1 (en) * 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2004055050A2 (en) * 2002-12-10 2004-07-01 Endocube Sas Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
JP2006517788A (ja) * 2002-12-20 2006-08-03 ミレニアム・ファーマシューティカルズ・インコーポレイテッド １５９８６、２１８８、２０７４３、９１４８、９１５１、９７９１、４４２５２、１４１８４、４２４６１、８２０４、７９７０、２５５５２、２１６５７、２６４９２、２４１１、１５０８８、１９０５、２８８９９、６３３８０、３３９３５、１０４８０、１２６８６、２５５０１、１７６９４、１５７０１、５３０６２、４９９０８、２１６１２、３８９４９、６２１６、４６８６３、９２３５、２２０１、６９８５、９８８３、１２２３８、１８０５７、２１６１７、３９２２８、４９９２８、５４４７６、６２１１３、６４３１６、１２２６４、３２３６２、５８１９８、２８８７、３２０５、８５５７、９６００、９６９３、４４８６７、５３０５８、５５５５６、５７６５８、２２０８、１０２５２、１０３０２、１４２１８、３３８７７、１０３１７、１０４８５、２５９６４、１４８１５、１３６３、１３９７、１４８２７、２１７０８、３８０１、６４６９８、２１７９または１３２４９を使用する癌を処置するための方法および組成物
TWI324608B (en) * 2003-02-28 2010-05-11 Oncotherapy Science Inc Genes and polypeptides relating to human colorectal cancers
EP1651775A2 (en) * 2003-06-18 2006-05-03 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1660677A2 (en) * 2003-08-20 2006-05-31 Oncotherapy Science, Inc. Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)
WO2005083086A2 (en) * 2004-02-27 2005-09-09 Oncotherapy Science, Inc. Epha4 as therapeutic target of prc and pdaca
EP2520652B1 (en) * 2004-04-09 2015-06-10 Genecare Research Institute Co., Ltd Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associates genes
AU2005250170A1 (en) * 2004-06-01 2005-12-15 Genimmune N.V. Peptides for inducing a CTL and/or HTL response to hepatitis C virus
US7915036B2 (en) 2004-09-13 2011-03-29 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions comprising T cell receptors and methods of use thereof
CN100381460C (zh) * 2004-11-30 2008-04-16 北京市肿瘤防治研究所 Her-2模拟抗原表位及含有该表位的肽
US20090075832A1 (en) * 2005-02-24 2009-03-19 Cemines, Inc Compositions and Methods for Classifying Biological Samples
ES2459492T3 (es) * 2005-02-25 2014-05-09 Oncotherapy Science, Inc. Vacunas de péptidos para cánceres de pulmón que expresan polipéptidos TTK, URLC10 o KOC1
CN100348614C (zh) * 2005-06-03 2007-11-14 北京大学 一种肝癌－睾丸特异性抗原蛋白质和抗原肽
ES2373055T3 (es) * 2005-08-09 2012-01-31 Oncotherapy Science, Inc. Péptido antígeno de rechazo de cáncer derivado de glipican-3 (gpc3) para uso en pacientes positivos a la hla-a2 y producto farmacéutico que comprende el antígeno.
JP4803460B2 (ja) * 2005-08-09 2011-10-26 学校法人 久留米大学 Ｈｌａ−ａ２４分子結合性扁平上皮癌抗原由来ペプチド
CN101287831B (zh) 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
WO2007064743A2 (en) * 2005-11-30 2007-06-07 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
ES2487637T3 (es) * 2006-04-10 2014-08-22 Genentech, Inc. Moduladores de PDZ Disheveled
KR101408173B1 (ko) * 2006-06-16 2014-06-16 온코세라피 사이언스 가부시키가이샤 Ｓｐａｒｃ 유래의 암 거절항원 펩티드 및 이를 포함하는 의약
EP1972639A3 (en) * 2007-03-07 2008-12-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP1983003A3 (en) * 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
ES2632123T3 (es) * 2007-08-20 2017-09-11 Oncotherapy Science, Inc. Péptido CDH3 y agente medicinal que comprende el mismo
EP2080812A1 (en) * 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
TWI580431B (zh) * 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
CA2775978A1 (en) * 2009-09-29 2011-04-07 Protagen Ag Marker sequences for pancreatic cancer diseases, pancreatic carcinoma and use thereof

Also Published As

Publication number Publication date
KR20150116463A (ko) 2015-10-15
CY1114590T1 (el) 2016-10-05
IL219040A0 (en) 2012-05-31
KR20130023407A (ko) 2013-03-07
EP2573109A3 (en) 2013-06-19
EP2476693A3 (en) 2012-10-03
BRPI0808421A2 (pt) 2017-08-29
EP2465864B1 (en) 2014-10-08
AR068302A1 (es) 2009-11-11
RU2464275C2 (ru) 2012-10-20
EP2573110A3 (en) 2013-09-04
MX337456B (es) 2016-03-03
EP2476694B1 (en) 2014-11-19
ES2540893T3 (es) 2015-07-14
HRP20141233T1 (hr) 2015-02-27
EP2465866A3 (en) 2012-10-10
KR20150064236A (ko) 2015-06-10
EP2121731A1 (en) 2009-11-25
EP2570428A2 (en) 2013-03-20
EP2565203A1 (en) 2013-03-06
EP2476692A3 (en) 2012-12-19
SI2476694T1 (sl) 2015-02-27
JP2013116895A (ja) 2013-06-13
PT2121731E (pt) 2013-10-24
PL2121731T3 (pl) 2014-01-31
PH12014501642A1 (en) 2015-12-02
MX2009009022A (es) 2010-03-03
EP2465866A2 (en) 2012-06-20
AU2008218463A1 (en) 2008-08-28
EP2594582A3 (en) 2013-08-14
JP5614761B2 (ja) 2014-10-29
EP2465865A2 (en) 2012-06-20
EP2570430A3 (en) 2013-07-10
IL219041A (en) 2014-12-31
JP5239103B2 (ja) 2013-07-17
EP2567971A2 (en) 2013-03-13
KR20150018895A (ko) 2015-02-24
KR101644871B1 (ko) 2016-08-02
KR20140130507A (ko) 2014-11-10
ES2541863T3 (es) 2015-07-27
EP2121731B1 (en) 2013-08-14
EP2476694A3 (en) 2013-04-24
NZ579768A (en) 2012-03-30
EP2476695A2 (en) 2012-07-18
JP2016094459A (ja) 2016-05-26
PL2476694T3 (pl) 2015-04-30
IL219042A (en) 2016-03-31
CA2678755C (en) 2016-04-26
EP2476694A2 (en) 2012-07-18
HK1172344A1 (en) 2013-04-19
EP2465865B1 (en) 2016-11-02
SI2121731T1 (sl) 2013-10-30
PT2465864E (pt) 2015-01-14
EP2465867A2 (en) 2012-06-20
IL219044A (en) 2014-12-31
EP2570429A3 (en) 2013-08-28
TWI615403B (zh) 2018-02-21
CY1115841T1 (el) 2017-01-25
AU2008218463A2 (en) 2009-11-26
CN102863514B (zh) 2014-12-10
TW201422637A (zh) 2014-06-16
ES2532708T3 (es) 2015-03-31
HK1172041A1 (en) 2013-04-12
TW200844111A (en) 2008-11-16
ZA200905881B (en) 2010-05-26
TWI494319B (zh) 2015-08-01
CN103351423B (zh) 2016-09-28
EP2465867B1 (en) 2015-04-01
HK1134507A1 (en) 2010-04-30
EP2476692B1 (en) 2015-04-15
HK1172345A1 (en) 2013-04-19
CA2992074C (en) 2021-01-05
JP2010519176A (ja) 2010-06-03
KR101543623B1 (ko) 2015-08-11
KR101511140B1 (ko) 2015-04-10
IL219044A0 (en) 2012-05-31
EP2570430A2 (en) 2013-03-20
EP2465864A2 (en) 2012-06-20
EP2573109A2 (en) 2013-03-27
IL200478A0 (en) 2010-04-29
ES2435194T3 (es) 2013-12-16
EP2465864A3 (en) 2012-10-03
EP2594581A3 (en) 2013-08-14
HRP20150108T1 (hr) 2015-05-08
EP2465867A3 (en) 2012-10-10
SG10201909675QA (en) 2019-11-28
KR20090121349A (ko) 2009-11-25
CN104292299A (zh) 2015-01-21
ES2530777T3 (es) 2015-03-05
EP2594581A2 (en) 2013-05-22
AU2008218463B2 (en) 2013-01-17
SI2465864T1 (sl) 2014-12-31
DK2121731T3 (da) 2013-10-21
HK1172043A1 (en) 2013-04-12
TW201433574A (zh) 2014-09-01
CO6190536A2 (es) 2010-08-19
KR101511134B1 (ko) 2015-04-28
WO2008102557A1 (en) 2008-08-28
PH12014501642B1 (en) 2015-12-02
TWI596109B (zh) 2017-08-21
EP2583976A3 (en) 2013-10-23
CA2919248A1 (en) 2008-08-28
IL219040A (en) 2014-12-31
NZ602119A (en) 2014-03-28
BRPI0808421B1 (pt) 2021-10-05
EP2573110A2 (en) 2013-03-27
HK1172042A1 (en) 2013-04-12
IL219043A (en) 2014-12-31
IL219047A0 (en) 2012-05-31
EP2476693B1 (en) 2014-12-24
IL219045A0 (en) 2012-05-31
EP2583976A2 (en) 2013-04-24
ES2527397T3 (es) 2015-01-23
JP5239104B2 (ja) 2013-07-17
TW201623325A (zh) 2016-07-01
IL219048A (en) 2015-07-30
CN101663315A (zh) 2010-03-03
KR20140121489A (ko) 2014-10-15
EP2570428A3 (en) 2013-07-10
IL219046A0 (en) 2012-05-31
EP2465865A3 (en) 2013-07-24
PL2465864T3 (pl) 2015-03-31
EP2476692A2 (en) 2012-07-18
JP5608953B2 (ja) 2014-10-22
MY155029A (en) 2015-08-28
JP5874158B2 (ja) 2016-03-02
KR101644877B1 (ko) 2016-08-03
EP2121731A4 (en) 2010-04-21
IL200478A (en) 2015-11-30
RU2009135020A (ru) 2011-03-27
EP2594582A2 (en) 2013-05-22
CA2992074A1 (en) 2008-08-28
SG179402A1 (en) 2012-04-27
KR101540000B1 (ko) 2015-07-29
TW201538522A (zh) 2015-10-16
IL219042A0 (en) 2012-05-31
MY173379A (en) 2020-01-21
SG10201506589WA (en) 2015-09-29
MX337417B (es) 2016-03-03
JP2010209060A (ja) 2010-09-24
HRP20131044T1 (hr) 2013-12-06
HK1172346A1 (en) 2013-04-19
MX359680B (es) 2018-09-28
JP2014210804A (ja) 2014-11-13
EP2567971A3 (en) 2013-06-26
TWI438207B (zh) 2014-05-21
IL219046A (en) 2015-02-26
NZ602122A (en) 2014-03-28
EP2574623A2 (en) 2013-04-03
CN104292299B (zh) 2017-09-29
NZ591704A (en) 2012-09-28
CN101663315B (zh) 2014-10-15
CA2678755A1 (en) 2008-08-28
CN102863514A (zh) 2013-01-09
KR20160045939A (ko) 2016-04-27
DK2476694T3 (en) 2014-12-08
IL219043A0 (en) 2012-05-31
EP2476695A3 (en) 2012-12-12
EP2574623A3 (en) 2013-07-17
CN103351423A (zh) 2013-10-16
EP2570429A2 (en) 2013-03-20
IL219048A0 (en) 2012-05-31
IL219041A0 (en) 2012-05-31
EP2476693A2 (en) 2012-07-18
DK2465864T3 (en) 2014-11-24
TWI610939B (zh) 2018-01-11
JP2013091645A (ja) 2013-05-16

Similar Documents

Publication Publication Date Title
UA100372C2 (ru) Выделенный пептид, способный индуцировать цитотоксические т-клетки, и его применение в качестве вакцины
CY1119366T1 (el) Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενου του γαστρεντερικου και του γαστρικου καρκινου
CO2018011668A2 (es) Neoantígenos y métodos de su uso
CY1119744T1 (el) Μια συνθεση που αποτελειται απο ογκο-σχετιζομενα πεπτιδια και ενα εμβολιο για την θεραπεια του γλοιοβλαστωματος και αλλων καρκινων
EA201792632A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
MX2020012778A (es) Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia y metodos para crear soportes para el uso contra el cancer de pancreas y otros tipos de cancer.
EA201300322A1 (ru) Композиция опухолеассоциированных пептидов и относящаяся к ним противораковая вакцина
CY1115999T1 (el) Νεα και ισχυρα mhc- κατηγοριας ιι πεπτιδια που προερχονται απο σουρβιβινη και νευροκανη
EA201891116A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов рака
EA201890635A1 (ru) Пептиды и комбинации пептидов для применения в иммунотерапии мелкоклеточного рака легких и других видов рака
EA201890027A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии эпителиального рака яичника и других видов рака
CL2011000086A1 (es) Anticuerpo aislado o proteina funcional contra el polipeptido baffr que inhibe la proliferacion de celulas b; secuencia nucleotidicas de dicho anticuerpo; vector y celula huesped que comprende dicha secuencia; y su uso para tratar enfermedades autoinmunes o neoplasias de celulas b.
MX2019005272A (es) Peptidos cancerigenos universales derivados de telomerasa.
EA201792484A1 (ru) Новые клеточные эпитопы и комбинации клеточных эпитопов для применения в иммунотерапии миеломы и других видов рака
EA201891638A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии нхл и других видов рака
EA201792044A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
EA201891074A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии хлл и других видов рака
BR112012011332A2 (pt) agentes direcionados para gadd45beta
EA201890440A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака предстательной железы и других видов рака
EA201891701A1 (ru) Пептиды и комбинации пептидов для применения в иммунотерапии немелкоклеточного рака легких и других видов рака
WO2011143656A3 (en) Compositions and methods of identifying tumor specific neoantigens
CR20210233A (es) NUEVOS PÉPTIDOS Y NUEVA COMBINACIÓN DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE PÁNCREAS Y OTROS TIPOS DE CÁNCER (Divisional 2017-0419)
EA201792671A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака пищевода и других видов рака
EA201892333A1 (ru) Иммунотерапия меланомы и других видов рака
EA201892159A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии омл и других видов рака